Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.60 |
| ▸ | CPA1 | P15085 | 6/20 | 0.38 |
| ▸ | CPA2 | P48052 | 6/20 | 0.38 |
| ▸ | CPA4 | Q9UI42 | 6/20 | 0.38 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.38 |
| ▸ | CPB1 | P15086 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 4/20 | 0.37 |
| ▸ | CTSD | P07339 | 1/20 | 0.37 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.37 |
| ▸ | GNPAT | O15228 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30524413 | 0.75 | ACE (1.00) | ACECPA1CPA2CPA4ACE2 | |
| SCHEMBL31181186 | 0.70 | GNPAT (0.56) | ACECPA1ACE2GNPAT | |
| SCHEMBL20694366 | 0.67 | GNPAT (0.39) | ACECPA1ACE2GNPAT | |
| SCHEMBL17424531 | 0.66 | GNPAT (0.60) | ACEGNPAT | |
| SCHEMBL23643116 | 0.66 | ALDH1A1 (0.39) | ACEGNPAT | |
| SCHEMBL20231649 | 0.65 | GNPAT (0.58) | ACEGNPAT | |
| SCHEMBL31162635 | 0.65 | GNPAT (0.51) | ACEBACE1CTSDBACE2GNPAT | |
| SCHEMBL21738190 | 0.64 | GNPAT (0.47) | ACEGNPAT | |
| SCHEMBL20230310 | 0.64 | GNPAT (0.56) | ACEGNPAT | |
| SCHEMBL22862417 | 0.63 | GNPAT (0.69) | GNPAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088730-A1 | USE OF ANGIOTENSIN CONVERTING ENZYME (ACE) DOMAIN SPECIFIC INHIBITORS TO INHIBIT OR ENHANCE CYTOKINE PRODUCTION AND ALTER IMMUNE RESPONSE | CEDARS-SINAI MEDICAL CENTER (US) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088730-A1 | USE OF ANGIOTENSIN CONVERTING ENZYME (ACE) DOMAIN SPECIFIC INHIBITORS TO INHIBIT OR ENHANCE CYTOKINE PRODUCTION AND ALTER IMMUNE RESPONSE | ACE, ACE2, AGT | ACE 1/4885CPA1 25/4885CPA2 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.